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Abstract Very small embryonic-like cells (VSELs) are a
population of stem cells residing in the bone marrow (BM)
and several organs, which undergo mobilization into
peripheral blood (PB) following acute myocardial infarction
and stroke. These cells express markers of pluripotent stem
cells (PSCs), such as Oct-4, Nanog, and SSEA-1, as well as
early cardiac, endothelial, and neural tissue developmental
markers. VSELs can be effectively isolated from the BM,
umbilical cord blood, and PB. Peripheral blood and BM-
derived VSELs can be expanded in co-culture with C2C12
myoblast feeder layer and undergo differentiation into cells
from all three germ layers, including cardiomyocytes and
vascular endothelial cells. Isolation of VSLEs using
fluorescence-activated cell sorting multiparameter live cell
sorting system is dependent on gating strategy based on their
small size and expression of PSC and absence of hematopoi-
etic lineage markers. VSELs express early cardiac and
endothelial lineages markers (GATA-4, Nkx2.5/Csx, VE-
cadherin, and von Willebrand factor), SDF-1 chemokine
receptor CXCR4, and undergo rapid mobilization in acute MI
and ischemic stroke. Experiments in mice showed differenti-
ation of BM-derived VSELs into cardiac myocytes and
effectiveness of expanded and pre-differentiated VSLEs in
improvement of left ventricular ejection fraction after myo-
cardial infarction.
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Introduction
Rapid progress in the field of experimental studies on
cardiovascular regeneration is being translated to the
clinical application of stem cells (SC) isolated from the
bone marrow (BM) or the myocardium (cardiac stem cells,
CSC). Aim of this approach is to promote the myocardial
recovery in patients with acute myocardial infarction (MI)
or to improve the cardiac function in the setting of ischemic
cardiomyopathy. So far, there is no proof that use of SC can
lead to bona fide cardiac regeneration and the mechanism
of beneficial effects observed in some studies is probably
mediated by paracrine effects leading to neoangiogenesis,
reduction of apoptosis, as well as recruitment of CSC to the
site of the ischemic injury [1]. At the current state of
clinical application of SC, there is no convincing data
showing the superiority of any particular-type cells or their
source, so heterogenous population of BM-derived mono-
nuclear cells (MNC) is used most often; however, some
recent studies assess the efficiency of selected subpopula-
tions of BMC, such as CD133+, CD34+CXCR4+ cells,
mesenchymal stromal cells (MSC), or CSC [2].
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BM-derived MNC novel types of SC carrying higher
reparatory potential are clearly needed. Such populations
include CSC [3], engineered BM-derived progenitor cells
(e.g., C-Cure) [4], allogeneic MSC [5], and pluripotent stem
cells (PSC). PSC can be produced using gene transfer
(induced pluripotent stem cells) [6, 7] or isolated from the
adult tissues (very small embryonic-like stem cells [VSELs]
[8]). Isolation of PSC from adult tissues seems to be very
promising approach because cells obtained in such way are
ethically acceptable, however efficient methods of isolation
and expansion in culture of human cells are still not
available [9, 10]. This review discusses the recent data on
characteristics and potential clinical application of VSELs.
Potential Role of PSC, Including VSELs in Adult
Organisms
Adult tissue PSC represent a population of epiblast-derived
progeny which survive into adulthood in different locations
in BM and solid organs. We hypothesized that these cells,
including VSELs, migrate during embryogenesis along
with hematopoietic stem cells (HSCs) to the BM, and their
migration follows the gradient of chemoattractants, includ-
ing chemokine stromal cell-derived factor-1 (SDF-1) [11].
Their potential role is to be a reserve population of SC and
tissue-committed progenitor cells which can be mobilized
after tissue injury. VSELs are primitive cells expressing the
markers typical for primordial germ cells including Stella,
Fragilis, Nobox, Hdac6, and CXCR4. We hypothesize that
quiescent VSELs serve as a reserve pool of PSC and are
part of the physiological mechanism of tissue repair and
renewal of resident SC [11]. Their quiescence is a safety
mechanism preventing the formation of teratomas.
Isolation and Sources of VSELs
Initially, rare population of VSELs was isolated from adult
murine BM by Kucia et al. by multiparameter fluorescence-
activated cell sorting (FACS). Our group established the
criteria for sorting of VSELs based on the presence of several
surface markers and the diameter of the cells. Figure 1 shows
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Fig. 1 Strategy for isolation of
VSELs from human peripheral
blood after mobilization with
C-CSF (MPB-VSELs) using
FACS-based live cell sorting
system. Gating strategy was
developed by using of the
synthetic beads of known
diameters (1, 2, 4, 6, 10, 15 μm)
(a) to define the extended
lymph-gate for subsequent
sorting (b). After lysis of eryth-
rocytes, mobilized peripheral
blood total nucleated cells
(TNCs) fraction is stained with
antibodies against hematopoietic
lineages markers (Lin), CD133
stem cell antigen (c), and CD45
pan-leukocytic antigen (d). Gate
R1 was set up to include objects
with diameter>2 μm. Events
included in region R1 were
analyzed for presence of hema-
topoietic lineages markers. Sub-
sequently, only lin
− events were
included into region R2, and
cells expressing CD133 antigens
were further isolated depending
on the presence of CD45 antigen
(gates R3-4). VSELs are
lin
−CD45
-CD133
+ cells
(gate R3) whereas hematopoietic
stem cells (HPCs) are included
in gate R4 and constitute popu-
lation of lin
−CD45
+CD133
+
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description of the protocol was published elsewhere. Briefly,
the initial step is the lysis of red blood cells to obtain the
fraction of nucleated cells. Erythrocyte lysis buffer is used
instead of Ficoll centrifugation because the latter approach
might deplete the population of very small cells [12].
Subsequently, cells are stained with antibodies against
Sca-1 (murine VSELs) or CD133 (human VSELs), pan-
hematopoietic antigen (CD45), hematopoietic lineages
markers (lin), and CXCR4 and sorted using a multiparam-
eter, live sterile cell sorting systems (MoFlo, Beckman
Coulter; FACSAria, Beckton Dickinson) [8]. We used
“extended lymphocyte gate” to include events with diam-
eter 2–10 μm, including approximately 95% of VSELs.
The width of the gate was validated by using synthetic
beads of predefined size (1–15 μm) [12]. Proper definition
of the gate is crucial because this area of the cytogram
includes not only cells, but also cellular debris [13, 14].
Several other approaches to define the population of small
cells were used, including ImageStream system, which is a
combination of FACS and immunofluorescent (IF) micro-
scope and allows to “decode” any particular events on
cytogram and visualize it to confirm morphology and
presence of markers consistent with VSELs phenotype
[13, 14]. VSELs were so far isolated in mice (BM,
peripheral blood, fetal liver, and several solid organs in
adult animals including brain, heart, retina, kidneys,
pancreas, skeletal muscles spleen, and thymus) and humans
[15]. In humans, VSELs were successfully isolated from
umbilical cord blood (UCB) and peripheral blood (PB).
Currently, our group investigates the presence of VSELs in
adult BM and myocardium [16, 17].
Structural, Molecular, and Functional Characteristics
of Freshly Isolated VSELs
VSELs confer a very small population of cells, and their
number is as low as 0.030±0.008% of total BM cells in
mice. Both murine BM-derived as well as human PB-
derived VSELs have significantly smaller diameter than
monocytes and granulocytes, and are larger than platelets
[4, 5]. In addition, some differences between murine and
human VSELs were observed. Human UCB- and PB-
derived VSELs consist of lin
−CD45-CXCR4+CD133+ and
consistently with differences in mean size of leukocytes and
RBC between humans and mice are larger than murine (~6–
7 μm) [13]. Population of Sca-1
+lin
−CD45
− cells was
enriched for PSC markers, such as Oct-4, Nanog, SSEA-1,
Rex1, and Dppa3, Rif-1. In addition, VSELs express
CXCR4 and migrated to the SDF-1 gradient. Several
imaging tools were used to define the morphology of VSELs
on the single cell level. Studies using transmission electron
microscopy confirmed that VSELs differed in several aspects
from HSC. As showed on Fig. 2,V S E L sa r es i g n i f i c a n t l y
smaller than HSCs (3–6v s .6 –8 μm) and have higher
nucleus/cytoplasm ratio. Nucleus is large, contains open-type
chromatin and is surrounded by the narrow rim of cytoplasm
with numerous mitochondria. Therefore, their morphology is
consistent with primitive PSC [8, 18, 19]. VSELs display
non-hematopoietic immunophenotype (lin
−CD45
−)a n dd o
not offer radioprotection in lethally irradiated recipient mice.
Freshly isolated and expanded VSELs do not form hemato-
poietic colonies in vitro [13, 20]. Distinct immunophenotype
and size are major criteria for isolation of VSELs, and the
presence of PSC markers was confirmed using real-time
RT-PCR, at protein level by IF staining and ImageStream
system. Importantly, because of the possibility of the
detection of pseudogenes raised by some investigators, our
group recently demonstrated that the promoters of Oct-4 and
Nanog in VSELs contain transcriptionally active chromatin
[21]. Importantly, VSELs and HSCs are different not only in
terms of their morphology.
Freshly isolated VSELs were expanded in co-culture
with C2C12 myoblast feeder layer and after 7–10 days,
formed sphere-like clusters consisting of a few hundred
cells resembling embryoid bodies (VSEL-derived spheres,
VSEL-DSs). VSEL-DSs expressed placenta-like alkaline
phosphatase. Co-culture allowed for expansion of VSELs,
and after isolation of expanded VSELs, we demonstrated
their capacity to differentiate into cell lines from all three
germ layers, such as mesodermal cardiomyocytes, ectoder-
mal neural cells, and endodermal pancreatic cells [22].
Importantly, the pluripotent features of VSELs are retained
in the population of mobilized to PB murine VSELs. Such
circulating cells showed expression of PSC markers on the
level similar to ES-D3 murine embryonic cells. Such
observations support the hypothesis that mobilized cells
might contribute to tissue repair because of their broad
differentiation capacity [18].
VSELs display morphological and molecular features of
PSCs. Several molecular markers are consistent with PSC
phenotype, such as Oct4 and Nanog, presence of bivalent
domains in promoters of developmentally important tran-
scription factors (Sox21, Nkx2.2, Dlx1, Lbx14, Hlx9), and
partially reactivate inactivated the X chromosome in female
PSCs. VSELs differentiate into cells from all three germ
layers. Importantly, the pluripotent features observed in
murine cells were not demonstrated in human VSELs. In
fact, VSELs neither fulfill the criteria for blastocyst
complementation nor show the ability to form teratomas in
immunodeficient mice. The quiescence of VSELs isolated
from adult tissue can be explained by their quiescence related
to epigenetic modification of crucial imprinted genes, such as
Igf2 and RasGRF1. Quiescence is probably a mechanism of
prevention against the formation of teratomas [21].
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Bone marrow-derived SC must undergo rapid mobiliza-
tion in order to participate in tissue repair. In addition,
there must be a variety of chemical signals to which the
VSELs must respond to orchestrate their homing and
engraftment into the ischemic or otherwise damaged
tissue (irradiation, burns) [23]. Data from animal studies
showed rapid mobilization of SC from the BM to the
peripheral blood, as evidenced by an increase of circulat-
ing cells enriched with early cardiac markers (GATA-4 and
Nkx2.5/Csx), which migrated along the SDF-1 gradient
[24, 25].
Acute Myocardial Infarction
Acute MI leads to a generalized inflammatory response
with increased production and release of inflammatory
markers, and also of chemoattractant factors such as kinins,
chemokines, cytokines, and growth factors, components of
the complement cascade. This coexists with subsequent
mobilization of SC and endothelial progenitor cells as well
as leukocytes [24, 26–28].
In healthy humans, a very small number of VSELs [0.8–
1.3 cells/μL] can be detected reflecting continuous efflux of
SC from the BM [10, 25, 28]. During acute MI, the number
of VSELs is significantly higher and the expression of
mRNA of PSC and cardiac markers is up-regulated [25].
Numerous hematopoietic and inflammatory cytokines
known to regulate mobilization of SC are up-regulated in
acute coronary syndromes. Several factors involved in
trafficking of VSELs are SDF-1, leukemia inhibitory factor,
hepatocyte growth factor, and stem cell factor-CD117 axes
[24, 29, 30]. Figure 3 shows the mechanisms of mobiliza-
tion and homing of VSELs in acute MI.
The number of mobilized VSELs is dependent on
several factors, such as age, presence of diabetes, and the
extent of myocardial damage [18]. In our hands, mobiliza-
tion of VSELs was reduced in elderly and diabetic patients
with acute MI [31]. Also, patients with more severely
impaired cardiac function (reduced left ventricular ejection
fraction, high levels of cardiac troponins) had reduced
number of circulating cells [25, 32].
Ischemic Stroke
Similar to acute MI, ischemic stroke was associated with
significantincreaseofthenumberofcirculatingVSELsinPB.
These cells expressed increased levels of mRNA for neural
markers (GFAP, nestin, beta-III-tubulin, Olig1, Olig2, Sox2,
Fig. 2 Representative images of
human peripheral blood-derived
VSEL and HSPC by
ImageStreamX system. Human
blood cells were stained for
markers distinguishing VSELs
such as: (1) CD45
pan-leukocytic antigen
(APC-Cy7, cyan), (2)
hematopoietic lineages markers
(FITC, green) and (3) stem cell
antigens CD133 (PE, yellow),
and CD34 (APC, violet). Nuclei
were stained with Hoechst
33342 dye. Images were
collected by imaging flow
cytometer-ImageStreamX
system. VSELs and HSPCs
were distinguished based on
CD45 antigen expression
J. of Cardiovasc. Trans. Res. (2011) 4:138–144 141and Musashi) as well as PSC markers (Oct-4, Nanog). This
suggests that mobilization of VSELs is an important
mechanism in different forms of tissue ischemia [33].
Physical Exercise
Physical exercise, especially a regular one, was shown to
increase the number and improve the function of circulating
SC and progenitor cells. Our preliminary data showed that
intensive treadmill exercise induced the transient mobiliza-
tion of VSELs into peripheral blood. An increased number
of VSELs was detected as early as after the exercise, and
circulating cells showed increased expression of mRNA for
PSC (Oct-4, Nanog), cardiac (GATA-4, Nkx2.5/Csx,
MEF2C), and endothelial markers (VE-cadherin). Mobili-
zation was negatively correlated with an extent of coronary
Fig. 3 The putative mechanism of mobilization and homing of
VSELs in acute myocardial infarction. Myocardial ischemia induces
increased expression of chemoattractants [chemokines (SDF-1),
growth factors (VEGF, HGF), cytokines (LIF)] and release of
phospholipids predominantly in infarct border zone. The increased
expression of chemoattractants in the ischemic organ creates the
reversal of chemoattractant gradient leading to the release of VSELs
from the bone marrow niches and their homing to the site of the
ischemic injury. Within the bone marrow niche, the mobilization of
VSELs is orchestrated by expression of matrix metaloproteinases and
activation of complement cascade. Also, phospholipids, such as
sphingosine-1-phosphate influence the mobilization of VSELs. In
peripheral blood in healthy subjects, VSELs can be detected at a very
low number. After ischemic injury, these cells are rapidly mobilized
into peripheral blood and the expression of pluripotent stem cell
markers, as well as early cardiac, endothelial, muscle, and neural
markers is significantly increased. Hence, we hypothesized that
mobilization of VSELs is a part of reparatory mechanism activated
in the setting of acute myocardial infarction. Also, circulation of
VSELs might contribute to the pool of resident cardiac stem cells
142 J. of Cardiovasc. Trans. Res. (2011) 4:138–144artery disease in angiography (one- vs. two- and three-
vessel disease) [submitted].
Potential Application of VSELs and VSEL-Enriched
Populations in Clinical Trials
The measurement of the number of VSELs might, after
validation in larger population, serve as a prognostic marker
in acute MI because the preliminary data showed inverse
correlation with the extent of myocardial injury and
presence of co-morbidities, such as diabetes. Another
approach is to use the cells for prevention of left ventricular
dysfunction after MI. We developed a protocol for
expansion and differentiation of BM-derived VSELs into
cardiac myocytes. The differentiation of murine VSEL-
derived cardiac myocytes (CM) closely resembles the same
process in embryonic stem cell-derived CM [8, 34]. Dawn
et al. showed that direct intramyocardial injection of freshly
isolated VSELs in mice with reperfused MI improved
global and regional left ventricular contractility. Moreover,
the beneficial effects were observed after 35 days of follow-
up. The histopathology study showed rare VSEL-derived
cardiac myocytes in the recipients' heart muscle [35].
Additionally, expansion and pre-differentiation of VSELs
in cardiopoiesis-guided media for 5 days before the
injection increased their effectiveness leading to increase
of left ventricular ejection fraction, myocardial systolic
thickening, and attenuated remodeling after 35 days post-
MI [36]. Clinical studies using autologous VSELs are
needed to validate these promising experimental data,
providing that clinically approved protocols for cell
expansion and differentiation are available. Several other
emerging stem cell technologies such as CSC, genetically
engineered bone marrow progenitor cells (e.g., EPC over-
expressing endothelial nitric oxide synthase), allogeneic
bone marrow-derived MSC and cardiopoiesis-guided bone
marrow-derived mesenchymal cardiopoietic cells are under
translation into clinical use.
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